Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

SPARC is expected to see a rise in revenues compared to the previous year, which may signal a favorable investment opportunity. If supported by strong fundamental data, this growth could attract investors looking for companies with improving financial prospects and potential for long-term gains.

Financial Ratios:

currentRatio 0.02900
forwardPE 0.00000
debtToEquity 0.00000
earningsGrowth 0.00000
revenueGrowth -0.38900
grossMargins 0.52027
operatingMargins -8.68702
trailingEps -8.23000
forwardEps 55.40000

Sun Pharma Advanced Research Company Limited's current ratio is 0.029, suggesting that its cash reserves and current assets may not be sufficient to cover short-term debts. This indicates potential liquidity challenges, meaning the company might face difficulty meeting its immediate financial obligations without securing additional funds.
SPARC's low earnings and revenue growth suggest that the company's profits may shrink. This trend could indicate underlying financial struggles and pose challenges for SPARC's future profitability.

Price projections:

Price projections for SPARC
Price projections for SPARC



Recommendation changes over time:

Recommendations trend for SPARC
Recommendations trend for SPARC


The analysts' recent buy bias for SPARC indicates strong confidence in the stock's future performance. This could encourage more investors to view SPARC as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.